Is Bausch + Lomb a Good Investment Right Now in 2022?
Bausch + Lomb has a really interesting history and is obviously a big name in eye health care, but is it a worthwhile investment?
Oct. 13, 2022

This article can be found in the MyWallSt App, alongside an audio companion. Sign up today for a free account and get access to dozens of expertly written articles and analyst opinion pieces every month.

Bausch + Lomb Corp. (NYSE: BLCO) was founded in 1853 by John Bausch and Henry Lomb, both German immigrants. They established a small workshop that produced monocles in Rochester, New York, specializing in vulcanite rubber eyeglass frames. During the civil war, blockades led to sharp increases in the price of gold and European horn, leading Bausch + Lomb spectacles to explode in popularity.

The company went on to produce glass lenses for a number of devices including microscopes and binoculars, as well as projectors, and camera lenses. It then partnered with Zeiss in Germany to produce eyeglass lenses. Beginning in 1914, Bosch + Lomb won a lucrative contract with the United States government to produce lenses for military equipment and eyeglasses for personnel. By 1930, military products represented 70% of total production. Bosch and Lomb founded Ray-Bans in 1936 for pilots.

It was the first company to bring hydrogel contact lenses to the market in 1971. In the 1980s the company began to restructure and move away from eyeglasses. This saw its eyewear division, including Ray-Ban, be sold to Luxottica Group for US$640 million

Bausch + Lomb was a public company listed on the NYSE, until it was acquired by private equity firm Warburg Pincus in 2007. In May 2013, it was announced that Canadian-based Valeant Pharmaceuticals would acquire Bausch + Lomb from Warburg Pincus for $8.57 billion in cash. The deal, which was approved by shareholders, included $4.2 billion earmarked to pay down Bausch + Lomb debt and closed on August 5, 2013.

On May 6, 2022, Bausch + Lomb (eye care) and Bausch Health (used to be called Valeant but the name was dropped after a disastrous expansion plan in 2018) were separated and Bausch + Lomb (eye care) IPO'd. This was done to help manage massive amounts of debt and allow the two companies to be measured on their own. Bausch Health did well throughout the pandemic while eye care struggled

And, almost exactly a year after announcing the eye care spinout, Bausch Health outlined plans for another. Its $300 million aesthetics devices division, Solta Medical, would separately head to the Nasdaq to help further chip away at the company's past debts and $350 million owed to holders of outstanding senior notes.

But what about its business now?

Top Ten Stocks To Buy Now
Commit to your future wealth today and join 1000s of subscribers receiving:
  • New stock picked every week out of 60,000 worldwide
  • Ten Foundational stocks to hold until 2034
  • A library of 60 stocks with analysis
  • 10 year Track record of performance
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

The Home of Successful Investing.

© 2024 MyWallSt Ltd. All rights reserved.







This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.